ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
Copyright: © 2022 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
In silico algorithm for optimization of pharmacokinetic studies of [25Mg2+]porphyrin-fullerene nanoparticles
About authors
1 Mendeleev University of Chemical Technology, Moscow, Russia
2 Pirogov Russian National Research Medical University, Moscow, Russia
3 Semenov Federal Research Center for Chemical Physics, Moscow, Russia
Correspondence should be addressed: Valentin V. Fursov
Ostrovityanova, 1, Moscow, 117997, Russia; ur.liam@vosrufv
About paper
Funding: the study was funded by by the Ministry of Science and Higher Education of the Russian Federation, grant No. 075-15-2020-792 (Unique identifier RF-190220X0031)
Author contribution: Fursov VV — in silico study supervision, concept, hypothesis, structure, modeling, manuscript writing; Zinchenko DI — modeling, code, manuscript writing; Namestnikova DD — in vivo experiments; Kuznetsov DA — general supervision, data interpretation and analysis, planning of experiments.
Compliance with ethical standards: the study was approved by the ethical review board at the Pirogov Russian National Research Medical University (protocol № 140 of 15 December 2014) and the local committee for surveillance of the maintenance and use of laboratory animals (protocol № 13/2020 of 08 October 2020, protocol № 24/2021 of 10 December 2021).
Received: 2022-07-05
Accepted: 2022-07-18
Published online: 2022-07-22
|
Fig. 1. A scheme of the five-compartment model of РМС16 pharmacokinetics
Fig. 2. Pharmacokinetic curves built using the model (shown in black) compared with experimental data for the brain, the liver and the heart (Khm = 0.50; Klp = 2; Khp = 0.50; Klm = 6; Khm = 0.50; Ke = 0.077; Kbp = 0.70; Kbm = 0.70; Kism = 0.10; Kisp = 0.10)
Table 1. CZE system calibration: correlation of the internal standard content and optical density values of the identified РМС16 fractions (Rt = 7.0 min)
Note: CZE-analyzed samples comprised S125 aceton-soluble cytosolic pool mixed in a known proportion with NP (1.0–1000.0 ng/mg of the total cytosolic protein). Correlation coefficient r = 0.86; n = 6. NP retention time (effective migration) Rt = 7.0 min. CZE-analyzed sample: S125 aceton-soluble pool mixed in a known proportion with the target compound PMC16–RX (1.0–200.0 ng/mg of protein). Correlation coefficient r = 0.86; n = 6.
Table 2. Permeability of the blood-brain barrier for PMC16-RX and pharmacophore internalization by brain cells
Note: 20 mg of PMC16-RX per 1.0 kg rat body weight intravenously, measured 12 h post-injection.
